QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration ...
Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still ...
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...
BRAF exon 15 (7q34) mutation heterogeneity in metastatic and primary melanomas. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text ...
Around half of all cutaneous melanomas carry a BRAF mutation, with the majority of these being V600E. (Nasekom/iStock/Getty Images Plus) The FDA has signed off on Labcorp’s companion diagnostic for ...
This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the transfer time, which can be streamlined by pathology reflex testing. Delays in TAT affect the timing ...
Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...
"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...
NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results